Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258097 | 0.94 | FASN (0.33) | FASNCYP3A4CYP2C9APP | |
| SCHEMBL2396510 | 0.93 | FASN (0.35) | FASNCYP3A4CYP2C9APP | |
| SCHEMBL12625784 | 0.92 | FASN (0.33) | FASNCYP3A4CYP2C9APP | |
| SCHEMBL12625005 | 0.91 | GRM2 (0.33) | FASNCYP3A4CYP2C9APP | |
| SCHEMBL13002576 | 0.90 | FASN (0.39) | FASNCYP3A4CYP2C9APP | |
| SCHEMBL17070262 | 0.90 | CYP3A4 (0.33) | FASNCYP3A4CYP2C9APP | |
| SCHEMBL2398862 | 0.90 | FASN (0.34) | FASN | |
| SCHEMBL12625823 | 0.90 | FASN (0.31) | FASN | |
| SCHEMBL19829752 | 0.88 | FASN (0.33) | FASN | |
| SCHEMBL12625975 | 0.88 | FASN (0.35) | FASNCYP3A4CYP2C9APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211513-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211513-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-8211513-B2 | Liquid-crystalline compounds and liquid-crystalline media | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2368966-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| EP-2368966-A1 | Liquid crystalline compounds and liquid crystalline media | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110233466-A1 | LIQUID-CRYSTALLINE COMPOUNDS AND LIQUID-CRYSTALLINE MEDIA | CFB, CFD, LCT | FASN 2699/4885CYP3A4 1213/4885CYP2C9 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.